Cogent Biosciences

Yahoo Finance • 4 days ago

What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge

Superstring Capital Management cut its stake in UroGen Pharma Ltd. (NASDAQ:URGN), selling 330,983 shares in the first quarter in an estimated $6.64 million trade based on average quarterly pricing, according to a May 14, 2026, SEC filing.... Full story

Yahoo Finance • 4 days ago

Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally

Superstring Capital Management disclosed a new position in Vir Biotechnology(NASDAQ:VIR), acquiring 730,548 shares in the first quarter. The estimated transaction value was $5.82 million based on quarterly average pricing. What happened... Full story

Yahoo Finance • 10 days ago

Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish

Octagon Capital Advisors cut its stake in Dianthus Therapeutics(NASDAQ:DNTH) by 470,000 shares, an estimated $27.22 million trade based on quarterly average pricing, according to a May 15, 2026 SEC filing. What happened According to a SE... Full story

Yahoo Finance • 11 days ago

Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares

On May 15, 2026, HighVista Strategies disclosed it sold 70,503 shares of Maze Therapeutics(NASDAQ:MAZE) in Q1 2026, an estimated $3.11 million trade based on quarterly average pricing. What happened According to a Securities and Exchange... Full story

Yahoo Finance • 11 days ago

Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares

On May 15, 2026, HighVista Strategies disclosed a purchase of 96,218 shares of Tyra Biosciences(NASDAQ:TYRA), estimated at $3.11 million based on quarterly average pricing. What happened According to its SEC filing dated May 15, 2026, Hi... Full story

Yahoo Finance • 11 days ago

This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million

HighVista Strategies reported a sale of 238,243 shares of Viridian Therapeutics(NASDAQ:VRDN) in its May 15, 2026, SEC filing, an estimated $7.08 million trade based on quarterly average pricing. What happened According to a SEC filing da... Full story

Yahoo Finance • 12 days ago

Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares

What happened According to a Securities and Exchange Commission (SEC) filing dated May 15, 2026, Patient Square Capital LP disclosed the purchase of 210,000 shares of Nektar Therapeutics(NASDAQ:NKTR). The estimated value of the trade was... Full story

Yahoo Finance • 13 days ago

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying.

Investor Stanley Druckenmiller’s Duquesne Family Office exited a 385,000 share position in Alphabet in the first quarter. Continue Reading... Full story

Yahoo Finance • last month

Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026

– Updated presentation on Cogent’s potent pan-KRAS(ON) inhibitor, CGT1263, showcasing its selectivity profile which could lead to reduction in skin toxicity associated with multi-RAS inhibitors – Updated presentation on Cogent’s brain pen... Full story

Yahoo Finance • 2 months ago

This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch

RTW Investments disclosed a significant buy of Cogent Biosciences(NASDAQ:COGT) in its February 17, 2026, SEC filing, adding 4,124,755 shares in a trade estimated at $115.95 million based on quarterly average pricing. What happened Accord... Full story

Yahoo Finance • 2 months ago

High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding

Kynam Capital Management disclosed in a February 17, 2026, SEC filing that it sold 1,720,949 shares of Cogent Biosciences(NASDAQ:COGT), an estimated $48.38 million trade based on quarterly average pricing. What happened According to a SE... Full story

Yahoo Finance • 2 months ago

This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know

Kynam Capital Management trimmed its stake in Viridian Therapeutics(NASDAQ:VRDN), selling 2,957,386 shares in the fourth quarter, an estimated $81.11 million transaction based on quarterly average pricing, according to a February 17, 2026,... Full story

Yahoo Finance • 2 months ago

This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know

Kynam Capital Management reduced its position in CG Oncology(NASDAQ:CGON), selling 1,059,375 shares in the fourth quarter for an estimated $43.84 million based on quarterly average pricing, according to a February 17, 2026, SEC filing. Wh... Full story

Yahoo Finance • 2 months ago

Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish

Kynam Capital Management disclosed in a February 17, 2026, Securities and Exchange Commission (SEC) filing that it sold 469,041 shares of Syndax Pharmaceuticals(NASDAQ:SNDX), an estimated $8.18 million trade based on quarterly average pric... Full story

Yahoo Finance • 2 months ago

Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026

On February 17, 2026, Boone Capital Management sold out its entire Cogent Biosciences(NASDAQ:COGT) stake, liquidating 945,042 shares previously worth $13.57 million. What happened According to an SEC filing dated February 17, 2026, Boone... Full story

Yahoo Finance • 2 months ago

This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain

On February 17, 2026, Superstring Capital Management disclosed a new position in Axsome Therapeutics(NASDAQ:AXSM), acquiring 37,433 shares worth $6.84 million in the fourth quarter. What happened According to a Securities and Exchange Co... Full story

Yahoo Finance • 2 months ago

This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names

On February 17, 2026, Superstring Capital Management disclosed a new position in Definium Therapeutics(NASDAQ:DFTX), acquiring 425,202 shares in the fourth quarter. What happened According to a SEC filing dated February 17, 2026, Superst... Full story

Yahoo Finance • 2 months ago

This Biotech Fund Sold $8 Million of Terns Stock Last Quarter, but Here's Why It Still Seems Very Bullish

On February 17, 2026, Superstring Capital Management reported selling 345,869 shares of Terns Pharmaceuticals(NASDAQ:TERN) in the fourth quarter, an estimated $7.99 million trade based on quarterly average pricing. What happened Accordin... Full story

Yahoo Finance • 2 months ago

Is Cogent Biosciences (COGT) One of the Best Multibagger Stocks to Buy According to Billionaires?

Cogent Biosciences Inc. (NASDAQ:COGT) is one of the best multibagger stocks to invest in according to billionaires. On February 17, Cogent Biosciences released the earnings report for 2025 and entered 2026 with significant regulatory momen... Full story

Yahoo Finance • 2 months ago

This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision

Key Points Deerfield Management Company bought 418,538 Vera Therapeutics shares in the fourth quarter; the estimated trade size was $14.87 million. Meanwhile, the quarter-end position value rose by $99.77 million, reflecting both the new... Full story